Long-term antipsychotic polypharmacy: How does it start, why does it continue?

Therapeutic Advances in Psychopharmacology

Volumn 2, Issue 1, 2012, Pages 5-11

  Grech, Patrice ^a   Taylor, David ^a  

^a NONE

Author keywords

antipsychotics; polypharmacy; schizophrenia

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG INFORMATION; ELECTRONIC MEDICAL RECORD; FEMALE; HUMAN; MALE; MEDICAL DOCUMENTATION; MONOTHERAPY; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; TREATMENT DURATION;

EID: 84997930612     PISSN: 20451253     EISSN: 20451261     Source Type: Journal    
DOI: 10.1177/2045125311430110     Document Type: Article

References (17)

1. Centorrino F. Goren J.L. Hennen J. Salvatore P. Kelleher J.P. Baldessarini R.J. (2004) Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. Am J Psychiatry 161: 700–706.
2. Correll C.U. Frederickson A.M. Kane J.M. Manu P. (2007) Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res 89: 91–100.
3. Correll C.U. Rummel-Kluge C. Corves C. Kane J.M. Leucht S. (2009) Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull 35: 443–457.
4. Elie D. Poirier M. Chianetta J. Durand M. Gregoire C. Grignon S. (2010) Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder. J Psychopharmacol 24: 1037–1044.
5. Gilmer T.P. Dolder C.R. Folsom D.P. Mastin W. Jeste D.V. (2007) Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999–2004. Psychiatr Serv 58: 1007–1010.
6. Kane J.M. Correll C.U. Goff D.C. Kirkpatrick B. Marder S.R. Vester-Blokland E. et al. (2009). A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J Clin Psychiatry 70: 1348–1357.
7. Kapur S. Roy P. Daskalakis J. Remington G. Zipursky R. (2001) Increased dopamine D2 receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine. Am J Psychiatry 158: 311–314.
8. National Institute for Health and Clinical Excellence (2009) Schizophrenia: core interventions in the treatment and management of schizophrenia in adults in primary and secondary care (update). Clinical Guidance 82. National Institute for Health and Clinical Excellence.
9. Paton C. Barnes T.R. Cavanagh M.R. Taylor D. Lelliott P. (2008) High-dose and combination antipsychotic prescribing in acute adult wards in the UK: the challenges posed by p.r.n. prescribing. Br J Psychiatry 192: 435–439.
10. Ray W.A. Chung C.P. Murray K.T. Hall K. Stein C.M. (2009) Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 360: 225–235.
11. Sparshatt A. Jones S. Taylor D. (2008) Quetiapine: dose-response relationship in schizophrenia. CNS Drugs 22: 49–68.
12. Stahl S.M. (1999) Antipsychotic polypharmacy, Part 1: Therapeutic option or dirty little secret? J Clin Psychiatry 60: 425–426.
13. Suzuki T. Uchida H. Tanaka K.F. Nomura K. Takano H. Tanabe A. et al. (2004) Revising polypharmacy to a single antipsychotic regimen for patients with chronic schizophrenia. Int J Neuropsychopharmacol 7: 133–142.
14. Taylor D. Mir S. Mace S. Whiskey E. (2002) Co-prescribing of atypical and typical antipsychotics – prescribing sequence and documented outcome. Psychiatr Bull 26: 170–172.
15. Taylor D. Young C. Paton C. (2003) Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. J Clin Psychiatry 64: 30–34.
16. Taylor D. Paton C. Kapur S. (2009) The Maudsley Prescribing Guidelines, 10th edition. London: Informa Healthcare.
17. Waddington J.L. Youssef H.A. Kinsella A. (1998) Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatry 173: 325–329.